News

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Ca…
Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...